Lea Mertens
@leamert.bsky.social
Passionate psychedelic researcher & PhD candidate at the CIMH, Mannheim, Germany. Licensed psychotherapist (CBT)
Reposted by Lea Mertens
New long-read theory paper in Psychological Review:
Im short, we propose that effective psychedelic therapy employs the uniquely context-dependent effects of psychedelic drugs to engage & augment the same psychological change processes that underlie all effective psychotherapies.
Full text below ⬇️
Im short, we propose that effective psychedelic therapy employs the uniquely context-dependent effects of psychedelic drugs to engage & augment the same psychological change processes that underlie all effective psychotherapies.
Full text below ⬇️
October 10, 2025 at 8:22 PM
New long-read theory paper in Psychological Review:
Im short, we propose that effective psychedelic therapy employs the uniquely context-dependent effects of psychedelic drugs to engage & augment the same psychological change processes that underlie all effective psychotherapies.
Full text below ⬇️
Im short, we propose that effective psychedelic therapy employs the uniquely context-dependent effects of psychedelic drugs to engage & augment the same psychological change processes that underlie all effective psychotherapies.
Full text below ⬇️
Goodbye lake como and thank you for a wonderful break after an intense few months of data analysis, paper writing and preparing for my final psychotherapy license exam.
Now off to #ECNP2025, where I will be presenting the results of our episode study on Saturday. Meet me at poster PS01-0249!
Now off to #ECNP2025, where I will be presenting the results of our episode study on Saturday. Meet me at poster PS01-0249!
October 10, 2025 at 10:27 AM
Goodbye lake como and thank you for a wonderful break after an intense few months of data analysis, paper writing and preparing for my final psychotherapy license exam.
Now off to #ECNP2025, where I will be presenting the results of our episode study on Saturday. Meet me at poster PS01-0249!
Now off to #ECNP2025, where I will be presenting the results of our episode study on Saturday. Meet me at poster PS01-0249!
Reposted by Lea Mertens
Reframing Psychedelic Regulation: Tools, not Treatments
In this new article, we propose to regulate psychedelics as psychotherapeutic treatment tools rather than as treatments in their own right.
The use of anesthetics as treatment tools in surgery is a useful analogy.
In this new article, we propose to regulate psychedelics as psychotherapeutic treatment tools rather than as treatments in their own right.
The use of anesthetics as treatment tools in surgery is a useful analogy.
June 16, 2025 at 12:03 PM
Reframing Psychedelic Regulation: Tools, not Treatments
In this new article, we propose to regulate psychedelics as psychotherapeutic treatment tools rather than as treatments in their own right.
The use of anesthetics as treatment tools in surgery is a useful analogy.
In this new article, we propose to regulate psychedelics as psychotherapeutic treatment tools rather than as treatments in their own right.
The use of anesthetics as treatment tools in surgery is a useful analogy.
Reposted by Lea Mertens
BREAKING: German regulators have green-lit the EU's first psilocybin compassionate access program.
Unlike other countries’ pre-approval pathways, Germany’s does not require case-by-case regulatory approval and may see insurers cover costs.
Details: psychedelicalpha.com/news/germany...
Unlike other countries’ pre-approval pathways, Germany’s does not require case-by-case regulatory approval and may see insurers cover costs.
Details: psychedelicalpha.com/news/germany...
Germany Establishes EU’s First Psilocybin Compassionate Access Program - Psychedelic Alpha
Germany has become the first EU country to allow legal access to psilocybin under a compassionate use program for treatment-resistant depression. Unlike other countries’ pre-approval pathways, Germany...
psychedelicalpha.com
July 31, 2025 at 8:03 AM
BREAKING: German regulators have green-lit the EU's first psilocybin compassionate access program.
Unlike other countries’ pre-approval pathways, Germany’s does not require case-by-case regulatory approval and may see insurers cover costs.
Details: psychedelicalpha.com/news/germany...
Unlike other countries’ pre-approval pathways, Germany’s does not require case-by-case regulatory approval and may see insurers cover costs.
Details: psychedelicalpha.com/news/germany...
Glad to be at #ACNP2024 in Phoenix!
On Monday, I will be presenting the results of our episode trial in the session „Psychedelic-assisted Psychotherapy: From preclinical mechanisms to clinical applications“
alongside @fredbarrettphd.bsky.social, @kellietamashiro.bsky.social and Jennifer Mitchell.
On Monday, I will be presenting the results of our episode trial in the session „Psychedelic-assisted Psychotherapy: From preclinical mechanisms to clinical applications“
alongside @fredbarrettphd.bsky.social, @kellietamashiro.bsky.social and Jennifer Mitchell.
December 8, 2024 at 9:13 PM
Glad to be at #ACNP2024 in Phoenix!
On Monday, I will be presenting the results of our episode trial in the session „Psychedelic-assisted Psychotherapy: From preclinical mechanisms to clinical applications“
alongside @fredbarrettphd.bsky.social, @kellietamashiro.bsky.social and Jennifer Mitchell.
On Monday, I will be presenting the results of our episode trial in the session „Psychedelic-assisted Psychotherapy: From preclinical mechanisms to clinical applications“
alongside @fredbarrettphd.bsky.social, @kellietamashiro.bsky.social and Jennifer Mitchell.